2. Academic Validation
  3. Ponapensin, a cyclopenta[bc]benzopyran with potent NF-kappaB inhibitory activity from Aglaia ponapensis

Ponapensin, a cyclopenta[bc]benzopyran with potent NF-kappaB inhibitory activity from Aglaia ponapensis

  • Bioorg Med Chem Lett. 2007 Jan 1;17(1):109-12. doi: 10.1016/j.bmcl.2006.09.084.
Angela A Salim 1,  Alison D Pawlus,  Hee-Byung Chai,  Norman R Farnsworth,  A Douglas Kinghorn,  Esperanza J Carcache-Blanco
Affiliations

Affiliation

  • 1 Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
PMID: 17055270 DOI: 10.1016/j.bmcl.2006.09.084
Abstract

Two new compounds, a cyclopenta[bc]benzopyran, ponapensin (1), and an aglaialactone, 5,6-desmethylenedioxy-5-methoxy-aglalactone (2), together with nine known compounds were isolated from the CHCl(3) soluble extract of the leaves and twigs of Aglaia ponapensis. Their structures were established by spectroscopic data interpretation. Ponapensin (1) exhibited significant NF-kappaB inhibitory activity in an Elisa assay, and was found to be more potent than the positive control rocaglamide. All of the compounds isolated were also tested in a panel of human Cancer cell lines, with the known sterol E-volkendousin (3) and methyl rocaglate (aglafoline) found to be the only active substances.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-N2827
    Natural Product